We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit Therapeutics to Present at the Canaccord Genuity Growth
Conference
Oxford, UK, and Cambridge, MA, US, 1 August 2019 -- Summit Therapeutics
plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic
innovation, announces that Mr Glyn Edwards, Chief Executive Officer,
will present at the Canaccord Genuity Growth Conference on 8 August 2019
at 8:00am EDT in Boston.
A live webcast of the presentation will be available in the Investors
section of the Company's website,
https://www.globenewswire.com/Tracker?data=nl8x9aC_5LTFXByOeV_a3HR7-EPK_iD98bMTo9aQ14MSGmqXh3TzMqg_zC8x89bhcaRCvGOzpsp9xsaml4BEvAZZUj2rdhI4I7rFQk0Ye20=
www.summitplc.com. A replay of the webcast will be available from the
same location soon after the live presentation.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae
and are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate
Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
---------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina mailto:summit@consilium-comms.com
Virji summit@consilium-comms.com
---------------------------------
Lindsey Neville
-END-
(END) Dow Jones Newswires
August 01, 2019 07:00 ET (11:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
